Medication info

Toprasin Injection (Tobramycin) (Vial)

Prescription medicationIntramuscular injection · Intravenous injection
Ingredient · strength
Tobramycin›40mg / 1mL
Manufacturer / importer
Korea Union Pharma Co., Ltd.
Appearance
A colorless liquid in a colorless transparent vial
Packaging
1.5ml, 2ml, 2.5ml × 10 vials
Approval status
Active

MFDS item code 200401647 · Notified 2004.08.18

Summary

Main use
Treatment of systemic, organ, and bone infections, respiratory infections, and skin and wound infections
Who receives it
Adults · Children
Adult administration
Adults: For severe infections, administer 3 mg (potency)/kg of body weight per day of tobramycin in 3 divided doses by intravenous or intramuscular injection. For life-threatening infections, up to 5 mg (potency)/kg of body weight per day may be administered in 3~4 divided doses. When symptoms improve, reduce the dose to 3 mg (potency)/kg of body weight per day. Do not administer more than 5 mg (potency)/kg of body weight per day without measuring serum concentrations. The usual treatment duration is 7~10 days. Treatment may be extended depending on the severity of the infection; in such cases, monitor renal, vestibular, and auditory function (neurotoxicity occurs more frequently when treatment lasts longer than 10 days). Patients with renal failure Measure serum concentrations of this drug if possible. Administer an initial dose of 1 mg (potency)/kg of body weight, then reduce subsequent doses or extend the dosing interval. If serum concentrations of this drug cannot be measured directly, calculate the dose based on creatinine clearance or serum creatinine concentration, and adjust the dose while monitoring the patient's condition. However, these methods should not be used during dialysis. Dose reduction (dosing interval 8 hours): If creatinine clearance is 70mL/min or less, or the serum creatinine concentration is known, calculate the dose by multiplying the dose for a patient with normal renal function by the corresponding % value in <Table 1>. If the patient's steady-state serum creatinine concentration is known, an approximate dose can be calculated by dividing the dose for a patient with normal renal function by the serum creatinine concentration. Extension of dosing interval (same dose as for patients with normal renal function): If the patient's creatinine clearance cannot be measured and the patient's condition is stable, administer the dose at an interval in hours calculated by multiplying the serum creatinine concentration by 6. The dose may be adjusted according to age and symptoms. For intramuscular injection, dissolve in 1.5mL of saline injection or water for injection. For intravenous injection in adults, dilute the dose in 50~100mL of saline injection or 5% dextrose injection and administer by IV infusion over 20~60 minutes.
Child administration
Children: Administer 5 mg (potency)/kg of body weight per day in 3~4 divided doses by intravenous or intramuscular injection. Neonates (younger than 1 week): Administer 4 mg (potency)/kg of body weight per day in divided doses every 12 hours. For children, reduce the volume of diluent proportionally. Avoid IV infusion over less than 20 minutes, as serum tobramycin concentrations may exceed 12mg/mL. It is preferable not to administer this drug mixed with other drugs.

Ingredients

Manufacturer
Korea Union Pharma Co., Ltd.

Efficacy & effects

Treatment of systemic, organ, and bone infections, respiratory infections, and skin and wound infections

  • Meningitis
  • central nervous system infections
  • bronchitis
  • bronchiectasis
  • pneumonia
  • peritonitis
  • gastrointestinal infections
  • subcutaneous abscesses
  • boils
  • soft tissue infections
  • burns
  • postoperative wound infections
View approved original text

This medication is effective against a variety of harmful bacteria, including Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus. It is used for central nervous system infections such as meningitis, respiratory infections such as bronchitis and pneumonia, and gastrointestinal infections such as peritonitis. It is also effective against skin and soft tissue infections like subcutaneous abscesses, soft tissue infections, and burn infections, and can be used for postoperative infections and osteomyelitis. It is utilized for serious and recurrent urinary tract infections such as sepsis, pyelonephritis, and cystitis. This medication helps treat a wide range of bacterial infections.

How it is given

Adult administration

Adults: For severe infections, administer 3 mg (potency)/kg of body weight per day of tobramycin in 3 divided doses by intravenous or intramuscular injection. For life-threatening infections, up to 5 mg (potency)/kg of body weight per day may be administered in 3~4 divided doses. When symptoms improve, reduce the dose to 3 mg (potency)/kg of body weight per day. Do not administer more than 5 mg (potency)/kg of body weight per day without measuring serum concentrations. The usual treatment duration is 7~10 days. Treatment may be extended depending on the severity of the infection; in such cases, monitor renal, vestibular, and auditory function (neurotoxicity occurs more frequently when treatment lasts longer than 10 days). Patients with renal failure Measure serum concentrations of this drug if possible. Administer an initial dose of 1 mg (potency)/kg of body weight, then reduce subsequent doses or extend the dosing interval. If serum concentrations of this drug cannot be measured directly, calculate the dose based on creatinine clearance or serum creatinine concentration, and adjust the dose while monitoring the patient's condition. However, these methods should not be used during dialysis. Dose reduction (dosing interval 8 hours): If creatinine clearance is 70mL/min or less, or the serum creatinine concentration is known, calculate the dose by multiplying the dose for a patient with normal renal function by the corresponding % value in <Table 1>. If the patient's steady-state serum creatinine concentration is known, an approximate dose can be calculated by dividing the dose for a patient with normal renal function by the serum creatinine concentration. Extension of dosing interval (same dose as for patients with normal renal function): If the patient's creatinine clearance cannot be measured and the patient's condition is stable, administer the dose at an interval in hours calculated by multiplying the serum creatinine concentration by 6. The dose may be adjusted according to age and symptoms. For intramuscular injection, dissolve in 1.5mL of saline injection or water for injection. For intravenous injection in adults, dilute the dose in 50~100mL of saline injection or 5% dextrose injection and administer by IV infusion over 20~60 minutes.

Child administration

Children: Administer 5 mg (potency)/kg of body weight per day in 3~4 divided doses by intravenous or intramuscular injection. Neonates (younger than 1 week): Administer 4 mg (potency)/kg of body weight per day in divided doses every 12 hours. For children, reduce the volume of diluent proportionally. Avoid IV infusion over less than 20 minutes, as serum tobramycin concentrations may exceed 12mg/mL. It is preferable not to administer this drug mixed with other drugs.

Precautions

This medication should not be administered to certain patients. For example, patients who are allergic to this drug, aminoglycoside antibiotics, or bacitracin, those with ear diseases, severe kidney dysfunction, pregnant or breastfeeding women, patients with muscle disorders, those with bronchial asthma, and patients with eighth cranial nerve disorders should not use this medication. Additionally, this drug should be used cautiously in some patients. Special care is necessary for those with a family history of hearing loss, those with weak kidney or liver function, premature infants or newborns, the elderly, and patients who have difficulty with oral intake. This drug contains sodium bisulfite, which can cause allergic reactions or asthma attacks, so asthmatic patients should exercise particular caution. When using this drug, various side effects may occur, so careful monitoring is essential. Rarely, symptoms such as shock, gastrointestinal issues, blood abnormalities, central nervous system symptoms, liver and kidney dysfunction, skin rashes, allergic reactions, vitamin deficiency signs, injection site pain may occur. If any of these symptoms appear, consult a physician immediately. To prevent the development of resistant bacteria, it is advisable to check for susceptibility and administer the drug for only the minimum required duration. Furthermore, due to the risk of hearing damage and kidney impairment, the duration of treatment should ideally not exceed 10 days, and if prolonged use is necessary, regular blood concentration tests and hearing tests are required. This drug may interact with other medications, so caution is needed, especially when used with drugs that affect the kidneys or those with neuromuscular blocking effects. When used in conjunction with anticoagulants, frequent blood tests are required to reduce the risk of bleeding. During pregnancy, it may cause serious nerve damage to the newborn, so it should be used only when absolutely necessary, and during breastfeeding, it is safer to discontinue use. For newborns or low birth weight infants, kidney function is immature, so the dosage interval should be extended. Caution is also required in the elderly due to decreased kidney function and increased bleeding risk, and the dosage and administration interval should be adjusted accordingly. In cases of overdose, kidney dysfunction, hearing damage, and respiratory distress may occur, and healthcare personnel should be notified immediately for appropriate treatment. This medication may lose effectiveness when mixed with beta-lactam antibiotics for injection, so it must be administered through a different route. Finally, caution is advised when administering to patients receiving large-volume transfusions, as neuromuscular blocking symptoms and respiratory paralysis may occur. Some strains of bacteria with resistance to this drug have been reported, so it is important to decide on its use based on appropriate testing during infection treatment.

Side effects

Shock

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a sealed container to avoid contact with air, and should be kept at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the effectiveness and safety of the drug.

Appearance and packaging

Appearance

A colorless liquid in a colorless transparent vial

Package unit

1.5ml, 2ml, 2.5ml × 10 vials

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.